Das Barnali
Department of Biochemistry and Immunology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Four Bunglows, Andheri (W), Mumbai, 400053 India.
Indian J Clin Biochem. 2011 Jul;26(3):235-43. doi: 10.1007/s12291-011-0110-x. Epub 2011 Feb 18.
Method validation is pursued as the first step in establishing Lean-Total Quality Management in a new clinical laboratory, in order to eliminate error in test results. Validation of all the new tests were done (with particular reference to alkaline phosphatase) by verifying reference intervals, analytical accuracy and precision, inter-assay and intra-assay variations, analytical sensitivity, limit of detection, linearity and reportable range, i.e. (i) Analytical measurement range (AMR) and (ii) Clinically reportable range (CRR). Our obtained reference range was within that of the manufacturer's and showed high degree of analytical accuracy between two laboratories (r(2) = 0.99). Precision was comparable with the manufacturer's claim with inter-assay variation CV 1.04% and intra-assay variation CV 1.54%. Lowest limit of detection was 1.0324 ± 0.007 with CV 0.34%. AMR was also verified with CV 1.26 and 0.69%, for level 1 and level 2 control sera, respectively. The assay was linear with different dilutions. Lean concept was also verified with high recovery percentage. Validation ensures that accurate and precise results are reported in a clinically relevant turn around time.
方法验证是在新的临床实验室建立精益全面质量管理的第一步,目的是消除检测结果中的误差。通过验证参考区间、分析准确性和精密度、批间和批内变异、分析灵敏度、检测限、线性和可报告范围,即(i)分析测量范围(AMR)和(ii)临床可报告范围(CRR),对所有新检测项目(特别是碱性磷酸酶)进行了验证。我们获得的参考范围在制造商规定的范围内,并且两个实验室之间显示出高度的分析准确性(r(2) = 0.99)。精密度与制造商声称的相当,批间变异CV为1.04%,批内变异CV为1.54%。最低检测限为1.0324 ± 0.007,CV为0.34%。对于1级和2级对照血清,AMR也分别以CV为1.26%和0.69%进行了验证。该检测方法在不同稀释度下呈线性。精益理念也通过高回收率得到了验证。验证确保在临床相关的周转时间内报告准确和精确的结果。